FIELD: medicine; pharmaceutics.
SUBSTANCE: present invention relates to a method of treating cancer associated with prostate-specific membrane antigen (PSMA) expression. Proposed method comprises a step of administering to a host animal a therapeutically effective amount of a first compound of formula I, wherein said compound is complexed with 177Lu (I-Lu), in combination with a therapeutically effective amount of a second compound of formula I, wherein said compound is complexed with 225Ac (I-Ac). Also disclosed is the use of a compound of formula I-Lu for preparing a drug in combination with a compound of formula I-Ac.
EFFECT: as a result of treating cancer expressing PSMA, using a combination of compounds of formulas I-Lu and I-Ac, the disease is stabilized.
34 cl, 1 ex
| Title | Year | Author | Number |
|---|---|---|---|
| CANCER TREATMENT METHODS | 2019 |
|
RU2811406C2 |
| PSMA-TARGET COMPOUND AND ITS COMPLEX WITH RADIONUCLIDES FOR THERANOSTICS OF TUMOR EXPRESSING PSMA | 2022 |
|
RU2803734C1 |
| COMPLEX CONTAINING A PSMA-TARGETING COMPOUND BOUND TO A LEAD OR THORIUM RADIONUCLIDE | 2018 |
|
RU2795398C2 |
| METHOD FOR PREVENTING RADIATION INJURY OF GLANDS IN PERSON | 2020 |
|
RU2821523C1 |
| METHOD OF OBTAINING PSMA-TARGET COMPOUND COMPLEX BASED ON UREA Lu-PS-161 AND COMPLEX | 2023 |
|
RU2808636C1 |
| LYOPHILISATE BASED ON PROSTATE-SPECIFIC MEMBRANE ANTIGEN (PSMA) LIGANDS FOR PREPARING A RADIOPHARMACEUTICAL COMPOSITION IN FORM OF SOLUTION FOR INJECTIONS FOR TREATING PROSTATE CANCER, RADIOPHARMACEUTICAL COMPOSITION BASED ON IT FOR TREATING PROSTATE CANCER AND METHOD FOR PREPARING RADIOPHARMACEUTICAL COMPOSITION | 2023 |
|
RU2817970C1 |
| PARAMINOHYPURIC ACID (PAH) AS A KIDNEY PROTECTOR | 2020 |
|
RU2804349C2 |
| PSMA LIGANDS FOR IMAGING AND ENDORADIOTHERAPY | 2018 |
|
RU2807076C2 |
| THERAPEUTIC AGENTS AND USE THEREOF | 2012 |
|
RU2606773C2 |
| NEW PSA-BINDING AGENTS AND THEIR USE | 2018 |
|
RU2787105C2 |
